David T. Drummond ⎜Oct 24, 2017 ⎜ Customer
“Vancouver, BC – The Western Region Society of Nuclear Medicine (WRSNM) will honor Dr. François Bénard from the BC Cancer Agency with the presentation of their Distinguished Scientist Award. … Dr. Bénard is the Vice President, Research at the BC Cancer Agency, a Distinguished Scientist at the BC Cancer Agency Research Centre and Professor in the Department of Radiology at the University of British Columbia. He is also Associate Dean, Research at the University of British Columbia. In addition he holds the BC Leadership Chair in Functional Cancer Imaging. As a clinician scientist, his research interests are in positron emission tomography (PET), nuclear medicine, cancer imaging and targeted radionuclide therapy. (more…)
David T. Drummond ⎜Nov 15, 2016 ⎜ Supplier
Fast implementation of positron emission tomography (PET) into clinical and preclinical studies highly demands automated synthesis for the preparation of PET radiopharmaceuticals in a safe and reproducible manner. The aim of this study was to develop automated synthesis methods for these six 18F-labeled radiopharmaceuticals produced on a routine basis at the University of Pennsylvania using (more…)
David T. Drummond ⎜Oct 12, 2016 ⎜ Market
“Applications for molecular imaging technologies continue to increase and our industry continues to expand.” – David Drummond, Managing Director and Founder of isoSolutions
PET market poised for healthy growth By www.auntminnie.com link
October 11, 2016 — Driven by an increasing prevalence of chronic disorders and greater market penetration of PET systems, the global PET scanner sector will grow at a compound annual growth rate (CAGR) of 4.7% between 2016 and 2026, according to a new report by market research firm Future Market Insights. (more…)
David T. Drummond ⎜Sep 24, 2016 ⎜ Supplier
ln produced on a routine basis at UPENN with the Trasis AllinOne synthesizer.
By Ramona Delcea, Trasis Download pdf
David T. Drummond ⎜Sep 15, 2016 ⎜ Market
“This is a period of profound change for the Mo-99 supply network that is key to our industry.” – David Drummond, Managing Director and Founder of isoSolutions.
September 13, 2016 — Supplies of a key radioisotope used in nuclear cardiology scans could be disrupted next month when a Canadian nuclear reactor begins shutting down. U.S. healthcare providers could be left scrambling for new sources of molybdenum-99 (Mo-99) until other suppliers are able to step in and fill the void. (more…)